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ABSTRACT 
Objective: The present work aimed to synthesize some new substituted thiazoles incorporated to pyrazole moiety starting from 1-(3-
chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole-4-carboxaldehyde (1) in order to evaluate their anticancer activity and GSTP1 inhibition in a trail 
to explore new potential GST inhibitors and prevent the resistance of cells to anticancer drugs. In addition, investigate the probability of the most 
promising cytotoxic compounds to inhibit GSTP1 enzyme via molecular docking study.  
Methods: The carboxaldehyde 1 was treated with substituted thiosemicarbazide in absolute ethanol to give the corresponding thiosemicarbazone 
derivatives 2a–d. Cyclization of 2a-d either by ethyl bromoacetate, phenacyl bromide or maleic acid anhydride furnished new thiazole derivatives 
3, 4 and 5, respectively. These target compound 2-5 were screened for their GSTP1 inhibition and cytotoxic activity against HEPG-2 (human liver 
carcinoma), A549 (human lung carcinoma) and PC3 (human prostate carcinoma). Finally, molecular docking study of the most promising cytotoxic 
compounds against GSTP1 (PDB ID: 3GUS) is discussed. 
Results: Compounds 4a, 4b, and 4d were found to be highly active against HEPG-2 and PC-3 cancer cell lines with IC50 values ranging from 0.2±0.81 
to 9.3±2.08 μM compared to doxorubicin with IC50= 37.8±1.50 and 41.1±2.01 μM, respectively. Screening of 4a, 4b and 4d against GSTP1 showed 
higher inhibition activity with IC50 ranging from 1.5±0.18 to 4.3±0.29 μM. Docking studies revealed the promising binding affinities of the latter 
compounds which match with the binding mode of the ligand, NBDHEX toward the active site of GSTP1. 
Conclusion: Compounds 4a, 4b and 4d were distinguished by the higher anticancer activity against HEPG-2, A-549 and PC-3 cell lines of tumor and 
the remarkable inhibitory activity against GSTP1. 
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INTRODUCTION 
Glutathione transferases (GSTs) are a family of Phase II 
detoxification enzymes that catalyze the conjugation of glutathione 
(GSH) to a wide range of endogenous and exogenous electrophilic 
compounds to generate less toxic and more water soluble products 
easily to be eliminated. The glutathione S-transferase P1 (GSTP1) is 
considered as isoenzyme of the GST superfamily, which is over 
expressed in a variety of different human malignancies (particularly 
ovarian, non-small cell lung, breast, liver, pancreas, colon, and 
lymphomas), and it is over expressed in drug resistant tumors [1, 2]. 
Furthermore, in some cases, GSTP1 over expression has been linked 
to acquire multidrug resistance to chemotherapeutic agents by 
directly conjugating to chemotherapeutics [3-5]. Therefore, it 
appears to be important to find new GST inhibitors to prevent the 
resistance of cells to anticancer drugs [6, 7]. On the other hand, 
pyrazole and thiazole derivatives are reported to show anti-cancer 
activity against different types of carcinoma cell lines [8, 9]. Based 
on the previous observations, the present work aimed to synthesize 
some new heterocyclic systems incorporated to pyrazole and 
thiazole moieties starting from 1-(3-chlorophenyl)-3-(4-
methoxyphenyl)-1H-pyrazole-4-carboxaldehyde (1) [10] and 
evaluate their cytotoxic activity against HEPG-2, A-549 and PC-3 cell 
lines of tumor. The inhibitory activities of these compounds were 
screened against GSTP1, followed by molecular modeling studies to 
display the promising binding affinities of the most potent 
compounds with respect to binding mode of the ligand, NBDHEX (fig. 
1) toward the active site of GSTP1. 
MATERIALS AND METHODS 
General 
Melting points were determined on the digital melting point 
apparatus (Electrothermal 9100, Electrothermal Engineering Ltd, 
serial no. 8694, Rochford, United Kingdom) and are uncorrected. 
The micro analytical data were achieved on a Perkin-Elmer 2400 
analyzer (Perkin-Elmer, 940 Winter Street, Waltham, Massachusetts 
02451, USA) and were found within 0.4 % of the theoretical values. 
IR spectra were recorded on a Perkin-Elmer 1600 Fourier 
Transform Infrared Spectrophotometer (Perkin-Elmer). The NMR 
spectra were recorded on a Bruker Avance digital spectrometer 
(BRUKER, Germany) in DMSO-d6, and chemical shifts (δ) are 
reported in ppm units relative to the standard tetramethylsilane 
(TMS). Mass spectra (EI) were recorded at 70 eV with JEOL-JMS-
AX500 mass spectrometer (JEOL Ltd. 1-2, Musashino 3-chome 
Akishima, Tokyo 196-8558, Japan). The chemicals and solvents were 
of commercial grad and used without further purification. 1-(3-
Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole-4-carboxaldehyde 










Fig. 1: NBDHEX 
 
Synthesis 
Synthesis of compounds 2a-d 
A mixture of aldehyde 1 (6.25 g, 0.02 mol) and substituted 
thiosemicarbazide namely, cyclohexyl-thiosemicarbazide, phenyl-
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thiosemicarbazide. 4-fluorophenylthiosemi-carbazide or 4-methoxy-
phenylthiosemicarbazide (0.002 mol) in 30 ml absolute ethanol 
containing a few drops of concentrated hydrochloric acid was 
refluxed for 3 h. The formed precipitate was filtered, dried and 
recrystallized from absolute ethanol to give the title compounds 2a-d. 
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-4-cyclohexylthiosemicarbazide (2a)  
Yield: 88 %; MP: 247-249 °C; IR (KBr): 3431, 3334 (2 NH), 1593 
(C=N); 1H NMR (500 MHz, DMSO-d6): δ 1.02–1.70 (m, 10H, 
cyclohexyl ring), 1.90 (m, 1H, cyclohexyl ring), 3.83 (s, 3H, OCH3), 
7.00–8.65 (m, 8H, Ar-H), 8.20 (1H, s, CH=N), 9.07 (s, 1H, NH 
exchangeable with D2O), 9.20 (s, 1H, CH of pyrazole ring), 11.35 ppm 
(s, 1H, NH exchangeable with D2O); MS m/z (%): 469 (0.4, M++2), 
467 (1, M+), 200 (100); Anal. C24H26ClN5OS (467.5): Calcd: C, 61.59; 
H, 5.60; N, 14.96; Found: C, 61.42; H, 5.77; N, 14.88. 
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-4-phenylthiosemicarbazide (2b) 
Yield: 85 %; MP: 160-162°C; IR (KBr): 3441, 3318 (2 NH), 1597 
(C=N); 1H NMR (500 MHz, DMSO-d6): δ 3.81 (s, 3H, OCH3), 7.07–7.97 
(m, 13H, Ar-H), 8.31 (1H, s, CH=N), 9.24 (s, 1H, CH of pyrazole ring), 
9.75, 11.76 ppm (2s, 2H, 2NH exchangeable with D2O); MS m/z (%): 
463 (11, M++2), 461 (29, M+), 133 (100); Anal. C24H20ClN5OS (461.5): 
Calcd: C, 62.40; H, 4.36; N, 15.16; Found: C, 62.51; H, 4.22; N, 15.00.  
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-4-(4-fluorophenyl) thiosemicarbazide (2c) 
Yield: 80 %; MP: 263-265 °C; IR (KBr): 3436, 3318 (2 NH), 1597 
(C=N);1H NMR (500 MHz, DMSO-d6): δ 3.81 (s, 3H, OCH3), 7.06–7.96 
(m, 12H, Ar-H), 8.31 (1H, s, CH=N), 9.23 (s, 1H, CH of pyrazole ring), 
9.78, 11.78 ppm (2s, 2H, 2NH exchangeable with D2O);13C NMR 
(125.7 MHz, DMSO-d6): δ 55.71 (OCH3), 114.67-161.37 (Ar-C), 
140.60 (CH=N), 176.13 ppm (C=S); MS m/z (%): 481(0.4, M++2), 479 
(1.4, M+), 155 (100); Anal. C24H19ClFN5OS (479.5): Calcd: C, 60.06; H, 
3.99; N, 14.59; Found: C, 60.02; H, 3.77; N, 14.88. 
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-4-(4-methoxyphenyl) thiosemicarbazide (2d) 
Yield: 87 %; MP: >300°C; IR (KBr): 3429, 3302 (2 NH), 1596 (C=N); 
1H NMR (500 MHz, DMSO-d6): δ 3.77, 3.84 (2s, 6H, 2OCH3), 6.84–8.96 
(m, 12H, Ar-H), 8.29 (1H, s, CH=N), 9.21 (s, 1H, CH of pyrazole ring), 
9.66, 11.67 ppm (2s, 2H, 2NH exchangeable with D2O); MS m/z (%): 
493 (2, M++2), 491 (5, M+), 111 (100); Anal. C25H22ClN5O2S (491.5): 
Calcd: C, 61.03; H, 4.51; N, 14.23; Found: C, 61.24; H, 4.77; N, 14.36. 
Synthesis of compounds 3a-d 
A mixture of compound 2a-d (0.002 mol) and ethyl bromoacetate 
(0.23 ml, 0.002 mol) in 15 ml absolute ethanol containing few drops 
of piperidine was refluxed for 3 h. The solid precipitate was filtered, 
dried and recrystallized from absolute ethanol to give the 
compounds 3a-d. 
2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene) hydrazino)-3-cyclohexylthiazolidin-4-one (3a) 
Yield: 82 %; MP: 210-212 °C; IR (KBr): 1719 (C=O), 1599 (C=N); 1H 
NMR (500 MHz, DMSO-d6): δ 1.24–1.64 (m, 10H, cyclohexyl ring), 
2.27 (m, 1H, cyclohexyl ring), 3.84 (s, 3H, OCH3), 3.92 (s, 2H, 
thiazolidinone ring), 7.05–8.65 (m, 8H, Ar-H), 8.14 (1H, s, CH=N), 
9.21 (s, 1H, CH of pyrazole ring); MS m/z (%): 509 (0.9, M++2), 507 
(2, M+), 309 (100); Anal. C26H26ClN5O2S (507.5): Calcd: C, 61.47; H, 
5.16; N, 13.79; Found: C, 61.42; H, 5.37; N, 13.88. 
2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene) hydrazino)-3-phenylthiazolidin-4-one (3b) 
Yield: 79 %; MP: 189-191°C; IR (KBr): 1716 (C=O), 1612 (C=N); 
1H NMR (500 MHz, DMSO-d6): δ 3.79 (s, 3H, OCH3), 4.09 (s, 2H, 
thiazolidinone ring), 7.02–8.03 (m, 13H, Ar-H), 8.22 (1H, s, 
CH=N), 8.92 (s, 1H, CH of pyrazole ring);13C NMR (125.7 MHz, 
DMSO-d6): δ 55.67 (OCH3), 114.41-160.13 (Ar-C and 
thiazolidinone-C), 140.48 (CH=N), 172.47 ppm (C=O); MS m/z 
(%): 503 (11, M++2), 501 (25, M+), 77 (100); Anal. C26H20ClN5O2S 
(501.5): Calcd: C, 62.21; H, 4.02; N, 13.95; Found: C, 62.11; H, 
4.25; N, 14.13.  
2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene) hydrazino)-3-(4-fluorophenyl) thiazolidin-4-one (3c) 
Yield: 84 %; MP: 230-232 °C; IR (KBr): 1723 (C=O), 1614 (C=N); 1H 
NMR (500 MHz, DMSO-d6): δ 3.81 (s, 3H, OCH3), 4.09 (s, 2H, 
thiazolidinone ring), 7.03–8.08 (m, 12H, Ar-H), 8.24 (1H, s, CH=N), 
8.98 (s, 1H, CH of pyrazole ring);MS m/z (%): 493 (3.3, M++2), 519 
(9, M+), 111 (100); Anal. C26H19ClFN5O2S (519.5): Calcd: C, 60.06; H, 
3.68; N, 13.47; Found: C, 60.15; H, 3.85; N, 13.20. 
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-2-(3-(4-methoxyphenyl)-4-oxothiazolidin-2-
ylidinene) hydrazine (3d) 
Yield: 80 %; MP: 278-280°C; IR (KBr): 1712 (C=O), 1615 (C=N); 1H 
NMR (500 MHz, DMSO-d6): δ 3.80, 3.84 (2s, 6H, 2OCH3), 4.08 (s, 2H, 
thiazolidinone ring), 7.02–8.08 (m, 13H, Ar-H), 8.23 (1H, s, CH=N), 
8.98 (s, 1H, CH of pyrazole ring);MS m/z (%): 533 (0.9, M++2), 531 
(4.5, M+), 133 (100); Anal. C27H22ClN5O3S (531.5): Calcd: C, 60.96; H, 
4.17; N, 13.16; Found: C, 61.15; H, 4.02; N, 13.35. 
Synthesis of compounds 4a-d 
A mixture of compound 2a-d (0.002 mol) and maleic anhydride (0.2 
g, 0.002 mol) in 15 ml glacial acetic acid was refluxed for 10 h. The 
formed precipitate was filtered, dried and recrystallized from acetic 
acid to give the compounds 4a-d. 
2-(2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-
yl) methylene) hydrazono)-4-oxo-3-cyclohexylthiazolidin-5-yl) 
acetic acid (4a) 
Yield: 64 %; MP: 292-294 °C; IR (KBr): 3425 (OH), 1714, 1679 (2 
C=O), 1607 (C=N); 1H NMR (500 MHz, DMSO-d6): δ 1.05–1.91 (m, 10H, 
cyclohexyl ring), 2.26 (m, 1H, cyclohexyl ring), 3.01-3.34 (m, 2H, 
CH2COOH), 3.82 (s, 3H, OCH3), 4.30 (m, 1H, oxothiazolidine ring), 7.03–
8.45 (m, 8H, Ar-H), 8.10 (1H, s, CH=N), 9.36 (s, 1H, CH of pyrazole 
ring), 12.59 (s, 1H, COOH exchangeable with D2O);MS m/z (%): 567 
(0.5, M++2), 565 (1.4, M+), 309 (100); Anal. C28H28ClN5O4S (565.5): 
Calcd: C, 59.41; H, 4.99; N, 12.37; Found: C, 59.32; H, 5.22; N, 12.14. 
2-(2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-
yl) methylene) hydrazono)-4-oxo-3-phenylthiazolidin-5-yl) 
acetic acid (4b) 
Yield: 67 %; MP: 234-236°C; IR (KBr): 3434 (OH), 1725, 1679 (2 
C=O), 1604 (C=N);1H NMR (500 MHz, DMSO-d6): δ 3.11-3.32 (m, 2H, 
CH2COOH), 3.82 (s, 3H, OCH3), 4.34 (m, 1H, oxothiazolidine ring), 
7.02–8.98 (m, 13H, Ar-H), 8.18 (1H, s, CH=N), 9.37 (s, 1H, CH of 
pyrazole ring), 12.79 (s, 1H, COOH exchangeable with D2O);13C NMR 
(125.7 MHz, DMSO-d6): δ 39.54 (CH2COOH), 55.64 (OCH3), 114.03-
160.60 (Ar-C and oxothiazolidine-C), 140.55 (CH=N), 174.29, 184.99 
ppm (2 C=O); MS m/z (%): 561 (1, M++2), 559 (3, M+), 111 (100); 
Anal. C28H22ClN5O4S (559.5): Calcd: C, 60.05; H, 3.96;; N, 12.51; 
Found: C, 60.17; H, 4.23; N, 12.26.  
2-(2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-
yl) methylene) hydrazono)-4-oxo-3-(4-fluorophenyl) thiazo-
lidin-5-yl) acetic acid (4c) 
Yield: 62 %; MP: >300 °C; IR (KBr): 3432 (OH), 1720, 1673 (2 C=O), 
1605 (C=N); 1H NMR (500 MHz, DMSO-d6): δ 3.12-3.31 (m, 2H, 
CH2COOH), 3.82 (s, 3H, OCH3), 4.33 (m, 1H, oxothiazolidine ring), 
7.02–8.98 (m, 12H, Ar-H), 8.23 (1H, s, CH=N), 9.37 (s, 1H, CH of 
pyrazole ring), 12.78 (s, 1H, COOH exchangeable with D2O);MS m/z 
(%): 577 (0.1, M+), 111 (100); Anal. C28H21ClFN5O4S (577.5): Calcd: C, 
58.18; H, 3.66; N, 12.12; Found: C, 58.37; H, 3.45; N, 12.00. 
2-(2-(((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-
yl) methylene) hydrazono)-4-oxo-3-(4-methoxyphenyl) thiazo-
lidin-5-yl) acetic acid (4d) 
Yield: 69 %; MP: 255-257°C; IR (KBr): 3424 (OH), 1718, 1676 (2 
C=O), 1610 (C=N); 1H NMR (500 MHz, DMSO-d6): δ 3.11-3.31 (m, 2H, 
CH2COOH), 3.81, 3.83 (2s, 6H, 2 OCH3), 4.35 (m, 1H, oxothiazolidine 
ring), 7.02–8.98 (m, 13H, Ar-H), 8.18 (1H, s, CH=N), 9.38 (s, 1H, CH of 
Nossier et al. 
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pyrazole ring), 12.77 (s, 1H, COOH exchangeable with D2O);MS m/z 
(%): 589 (0.2, M+), 265 (100); Anal. C29H24ClN5O5S (589.5): Calcd: C, 
59.03; H, 4.10; N, 11.87; Found: C, 58.94; H, 4.32; N, 11.68. 
Synthesis of compounds 5a-d 
A mixture of compound 2a-d (0.002 mol) and phenacyl bromide (0.4 
g, 0.002 mol) in 15 ml absolute ethanol containing a few drops of 
piperidine was refluxed for 10 h. The formed precipitate was 





Yield: 85 %; MP: 185-187 °C; IR (KBr): 1594 (C=N); 1H NMR (500 
MHz, DMSO-d6): δ 1.03–1.90 (m, 10H, cyclohexyl ring), 2.28 (m, 1H, 
cyclohexyl ring), 3.84 (s, 3H, OCH3), 7.09–8.66 (m, 14H, Ar-H and 
thiazole ring), 8.14 (1H, s, CH=N), 9.21 (s, 1H, CH of pyrazole 
ring);MS m/z (%): 569 (3.4, M++2), 567 (1, M+), 44 (100); Anal. 
C32H30ClN5OS (567.5): Calcd: C, 67.65; H, 5.32; N, 12.33; Found: C, 




Yield: 82 %; MP: 203-205°C; IR (KBr): 1594 (C=N); 1H NMR (500 
MHz, DMSO-d6): δ 3.84 (s, 3H, OCH3), 7.10–8.66 (m, 19H, Ar-H and 
thiazole ring), 8.14 (1H, s, CH=N), 9.21 (s, 1H, CH of pyrazole ring); 
MS m/z (%): 563 (0.7, M++2), 561 (1.6, M+), 310 (100); Anal. 
C32H24ClN5OS (561.5): Calcd: C, 68.38; H, 4.30; N, 12.46; Found: C, 
68.41; H, 4.62; N, 12.23.  
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-2-(3-(4-fluorophenyl)-4-phenylthiazol-2(3H)-
ylidene) hydrazine (5c) 
Yield: 88 %; MP: 238-240 °C; IR (KBr): 1597 (C=N); 1H NMR (500 
MHz, DMSO-d6): δ 3.81 (s, 3H, OCH3), 7.06–8.30 (m, 18H, Ar-H and 
thiazole ring), 7.99 (1H, s, CH=N), 9.23 (s, 1H, CH of pyrazole ring); 
MS m/z (%): 581 (0.2, M++2), 579 (0.8, M+), 299 (100); Anal. 
C32H23ClFN5OS (579.5): Calcd: C, 66.26; H, 4.00; N, 12.07; Found: C, 
66.50; H, 3.92; N, 12.34. 
1-((1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl) 
methylene)-2-(3-(4-methoxyphenyl)-4-phenylthiazol-2(3H)-
ylidene) hydrazine (5d) 
Yield: 79 %; MP: 285-287°C; IR (KBr): 1596 (C=N); 1H NMR (500 
MHz, DMSO-d6): δ 3.79, 3.82 (2s, 6H, 2 OCH3), 6.87–8.63 (m, 17H, Ar-
H and thiazole ring), 8.10 (1H, s, CH=N), 9.20 (s, 1H, CH of pyrazole 
ring);13C NMR (125.7 MHz, DMSO-d6): δ 55.65, 55.72 (2 OCH3), 
113.77-160.18 (Ar-C and thiazole-C), 140.62 (CH=N); MS m/z (%): 
593 (2, M++2), 591 (5, M+), 265 (100); Anal. C33H26ClN5O2S (591.5): 
Calcd: C, 66.94; H, 4.43; N, 11.83; Found: C, 67.25; H, 4.36; N, 11.68. 
Biological assays 
Cell culture  
HEPG-2 (human liver carcinoma), PC-3 (human prostate carcinoma) 
and A-549 (human lung carcinoma) cell lines were obtained from 
the Karolinska Institute, Stockholm, Sweden. HEPG-2 cells were 
maintained in RPMI 1640 medium, while A-549 and PC-3 cancer 
cells were maintained in DMEM medium (Lonza Biowahittkar, 
Belgium). All the media were supplemented with 1 % antibiotic-
antimycotic mixture (10,000 U ml-1 potassium penicillin, 10,000 μg 
ml-1streptomycin sulfate, 25 μg ml-1 amphotericin B and 1 % L-
glutamine (Biowest, USA). 
MTT cytotoxicity assay 
Cell viability was investigated using MTT [3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide] (Bio Basic Canada Inc., 
Canada) assay [11-13]. This reaction depends on mitochondrial 
reduction of yellow MTT into purple formazan. All the preceding 
steps were carried out in sterile laminar air flow cabinet Biosafety 
class II level (Baker, SG403INT; Sanford, ME, USA). All incubations 
were done at 37 ˚C in 5 % CO2 incubator in the humidified 
atmosphere (Sheldon, TC2323; Cornelius, OR, USA). Cells were 
seeded into 96-well microtiter plastic plates at the concentration of 
(104 cells per well) and allowed to adhere for 24 h. Medium was 
aspirated and fresh medium (without serum) was added to the cells 
with various concentrations of the test compounds (100, 50, 25, 
12.5, 6.25, 3.12, 1.56 and 0.78 μg ml-1 in DMSO) and incubated for 48 
h. The medium was aspirated and 40 μl MTT salts (2.5 μg ml-1) was 
added to each correctly and incubated for a further 4 h. To stop the 
reaction and dissolve any formed formazan crystals, 200 μl of 10 % 
sodium dodecyl sulfate (SDS) were added to each well and incubated 
overnight at 37 ˚C. The amount of formazan product was measured 
at 595 nm with a reference wavelength of 620 nm as a background 
using a microplate reader (Bio-Rad Laboratories, model 3350, USA). 
For the untreated cells (negative control), medium was added 
instead of the test compounds. A positive control Adrinamycin® 
(doxorubicin) (Mr=579.9) was used as a known cytotoxic natural 
agent giving 100 % inhibition. Dimethyl sulfoxide (DMSO) was the 
vehicle used for dissolution of testing compound, and its final 
concentration on the cells was less than 0.2 %. IC50 was calculated 
for the samples and negative control (cells with vehicle) by the 
probit analysis using a simple t-test (SPSS statistical analysis 
software package/version 11.0, SPSS Inc., (IL), Chicago, USA). 
Inhibition of GSTP1 
Preparation of human placenta homogenates  
Twenty-five villous placental tissue samples were collected by blunt 
dissection within 30 min of delivery from women (age range 20 y) at 
El-galaa Hospital, Cairo, Egypt (participants gave informed consent). 
Placental tissue was dissected, placed in ice-cold 25 mM Tris-HCl 
buffer, pH 8.0 containing 1 mM DTT, 5 mM EDTA, homogenized 
immediately and centrifuged at 10,000 g for 25 min and saved at-4 
°C for further analyses [14]. 
Preparation of GST enzyme 
GST enzyme was prepared by using glutathione-Sepharose affinity 
chromatography. Glutathione S-transferase activity was determined 
by measuring the increase in the concentration of the conjugation 
product of GSH and 1-chloro-2,4-dinitrobenzene (CDNB) at 340 nm 
over 3 min at 25 °C. Unless otherwise stated, the assay mixture 
contained in a total volume of 1 ml, 0.1 M potassium phosphate 
buffer, pH 6.5, 1 mM CDNB in ethanol (final concentration of ethanol 
less than 4 %), 1 mM GSH, and the enzyme solution. One unit is 
equivalent to the amount of enzyme conjugating 1 μmol of CDNB in 1 
min at 25 °C. The extinction coefficient of the product was taken to 
be 9.6 mM-1 cm-1. Protein was estimated by using bovine serum 
albumin as standard [15]. 
Screening for GSTP1 inhibition  
Synthetic compounds (2-5) were screened for inhibition of the 
major cytosolic GSTP1 affinity purified from human placenta. The 
concentration of inhibitor required to bring about 50 % inhibition of 
GST activity, the IC50 value, was determined by plotting sigoidal dose 
response curves of enzyme activity versus log synthetic compound 
concentrations. 
Molecular modeling studies 
All the molecular modeling calculations and docking simulation 
studies were performed using Molecular Operating Environment 
(MOE®) [16] 2008.10. All the interaction energies and different 
calculations were automatically calculated. 
Target compounds optimization 
The target compounds were constructed as a 3D model using the 
builder interface of the MOE program. After checking their 
structures and the formal charges on atoms by 2D depiction, the 
following steps were carried out: the target compounds were 
subjected to a conformational search. All conformers were subjected 
to energy minimization; all the minimizations were performed with 
MOE until a RMSD gradient of 0.01 Kcal mol-1 and RMS distance of 
0.1 Å with MMFF94X force-field, and the partial charges were 
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automatically calculated. The obtained database was then saved as 
MDB file to be used in the docking calculations. 
Optimization of the enzyme's active site 
The X-ray crystallographic structure of GSTP1 receptor complexed 
with 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol, NBDHEX 
(PDB ID: 3GUS) [4] was obtained from the Protein Data Bank 
through the internet. The enzyme was prepared for docking studies 
by removing the ligand molecule, NBDHEX from GSTP1 receptor active 
site. Hydrogen atoms were added to the system with their standard 
geometry. Atoms' connection and type were checked for any errors 
with automatic correction. Selection of the receptor and its atoms' 
potential were fixed. MOE Alpha Site Finder was used for the active 
site search in the enzyme structure using all default items. Dummy 
atoms were created from the obtained alpha spheres. Re-docking of 
co-crystalline ligand to the receptor active sites to insure the docking 
method was efficient and the active pocket was saved as moe file to be 
used for docking simulation of the selected compounds. 
Docking of the target molecules 4a, 4b and 4d to the receptor 
active sites 
Docking of the conformation database of the target compounds was 
done using MOE-Dock software. The following methodology was 
generally applied via loading of the enzyme active site file, and the 
dock tool was initiated. The program specifications were adjusted to:  
-Dummy atoms as the docking site. 
-Triangle matcher as the placement methodology to be used. 
-London dG as scoring methodology to be used and was adjusted to 
its default values. 
The MDB file of the ligand to be docked was loaded and dock's 
calculations were run automatically. The obtained poses were 
studied, and the poses showed best ligand-enzyme interactions were 
selected and stored for energy calculations. The 2D interaction and 
stereo view for compounds 4b and 4d inside the active site of GSTP1 
enzyme were obtained and saved as both MOE and photo files. 
RESULTS AND DISCUSSION 
The synthetic routes of the target compounds are outlined in Scheme 
1. Condensation of 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-
pyrazole-4-carboxaldehyde (1) with substituted thiosemicarbazide 
in absolute ethanol gave the corresponding thiosemicarbazone 
derivatives 2a–d. The structures of 2a-d were well established from 
their microanalytical and spectral data. The IR spectrum of 2b 
revealed the appearance of two NH at λmax 3441 and 3318 cm-1 with 
a concomitant disappearance of the C=O band of the parent 1. Its 1H 
NMR spectrum (DMSO-d6) showed singlet at δ 8.31 ppm for anil 
proton (CH=N) and two singlet signals at δ 9.75 and 11.76 ppm 
corresponding to two NH protons (exchangeable with D2O). 
Cyclization of 2a, b, c or d either by ethyl bromoacetate, maleic acid 
anhydride or phenacyl bromide according to a reported method [17, 
18] furnished the novel thiazole derivatives 3, 4 and 5, respectively. 
Elemental and spectral analyses of 3-5 were in agreement with their 
structures. Compound 3c displayed disappearance of the two NH 
bands of the precursor 2 and an appearance of one C=O band in the 
IR spectrum at λmax 1723 cm-1. In addition, its 1H NMR illustrated the 
appearance of the characteristic two protons of thiazolidinone ring 
as singlet at δ 4.09 ppm. 1H NMR (DMSO-d6) spectrum of 4d 
revealed multiplet signal in the range δ 3.11-3.31 corresponding to 
aliphatic protons of CH2COOH moiety and another singlet signal at 
12.77 ppm which is attributed to the exchangeable COOH proton. In 
its IR spectrum, there are bands at 3424 cm–1 (OH), 1676 cm–1 (C=O) 
for the carboxylic acid group and 1718 cm–1 (cyclic ketone). Mass 
spectrum of compound 5d represented the molecular ion peak 
M+and M++2 at m/z 591 (5%) and 593 (2%) comprising 
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Scheme 1: Synthesis of compounds 2-5 
 
Cytotoxic activity 
Sixteen new target compounds 2-5 were preliminary screened 
for their in vitro cytotoxic activity against HEPG-2, PC-3 and A-
549 cell lines at a concentration of 100 μg ml-1(table 1). 
Compounds 4b and 4d displayed broad spectrum cytotoxic 
activity against the three cell lines. They showed potent activity 
of 97±1.10 and 92.9±1.62 % against HEPG2, 97.7±1.45 and 
96.9±3.25 % against PC-3 and 79.6±1.18 and 92.2±1.00 % 
against A-549, respectively. Whereas, compound 4a gave potent 
cytotoxic activity against two cell lines only, HEPG-2 and PC-3 
(98.4±1.30 and 98.5±2.60 %, respectively). 
Compounds that showed cytotoxic activity higher than 80 % at a 
concentration of 100 μg ml-1were used to calculate their IC50 values, 
which corresponds to the concentration required for 50 % inhibition 
of cell viability. Doxorubicin, which is one of the most effective 
anticancer agents, was used as a reference drug (table 2). In case of 
HEPG-2 cancer cell line, compounds 4a, 4b and 4d, revealed potent 
activity of IC50 of 7.2±1.85, 2.3±1.59 and 0.2±0.81 μM, respectively, 
higher than the reference drug doxorubicin of IC50 37.8±1.50 μM. 
Regarding PC-3 cell line, the results indicated that these three 
compounds showed potent cytotoxic activity with IC50 of 9.3±2.08, 
5.2±1.69 and 3.1±1.05 μM, respectively, higher than the reference 
drug doxorubicin with IC50 of 41.1±2.01 μM. 
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Table 1: Cytotoxic activity of the newly synthesized compounds against human carcinoma cell lines at 100 μg ml-1 
Compound a Growth inhibition (%) 
HEPG-2 PC-3 A-549 
2a 55.2±1.30 43.8±2.45 46.9±1.20 
2b 60.7±2.40 62.5±1.50 66.5±1.70 
2c 65±3.12 39.3±1.70 77.9±3.60 
2d 71.6±1.66 67.4±2.20 31.4±1.00 
3a 67.8±1.20 37.9±2.16 25.8±1.45 
3b 42.1±2.70 49.5±1.20 29.5±1.33 
3c 53.1±1.15 41.7±1.15 39±2.65 
3d 50.5±1.10 24.6±2.06 16.6±3.25 
4a 98.4±1.30 98.5±2.60 26±2.05 
4b 97±1.10 97.7±1.45 79.6±1.18 
4c 69±1.55 71.5±1.39 78.1±2.35 
4d 92.9±1.62 96.9±3.25 92.2±1.00 
5a 22.8±1.20 12.3±2.40 0 
5b 31.1±1.90 21.7±1.47 13.4±2.45 
5c 85.3±2.34 39.6±1.95 28.7±3.37 
5d 63.5±1.60 42.2±1.13 0 
Negative controlb 0 0 0 
Doxorubicin a 100±0.00 100±0.00 100±0.00 
a concentration of test compounds and positive control (doxorubicin) was 100μg ml-1, b Untreated cells in DMSO and its final concentration in the 
cells was less than 0.2 %, SEM = Standard error mean; each value is the mean of three values. 
 
Table 2: IC50 of the highly cytotoxic active compounds against human cancer cell lines 
Compounds IC50 (mean±SEM) (μM)  
HEPG-2 PC-3 A-549 
4a 7.2±1.85 9.3±2.08 >50 
4b 2.3±1.59 5.2±1.69 >50 
4d 0.2±0.81 3.1±1.05 >50 
Doxorubicin 37.8±1.50 41.1±2.01 48.8±1.30 
IC50: Compound concentration required to inhibit the cell viability by 50 %, SEM = Standard error mean; each value is the mean of three values. 




Inhibition percent (%) (mean±SEM)  IC50 (mean±SEM) (μM) 
2a 33.8±2.30 156.7±2.20 
2b 29.7±1.80 IN 
2c 16.9±0.90 IN 
2d 13.9±0.40 273.4±4.10  
3a 76.6±2.60 34.1±2.47 
3b 6.8±0.35 569.8±5.57  
3c 9.6±0.40 IN  
3d 7.6±0.25 IN 
4a 98.4±0.03 4.3±0.29 
4b 98.5±0.05 3.4±0.32 
4c 29.6±1.20 IN 
4d 98.8±0.03 1.5±0.18 
5a 88.3±0.10 41.9±2.10 
5b 38.3±1.70 124.8±2. 90 
5c 28.6±1.40 108.9±1.99 
5d 22.7±1.20 346.1±4.60 
a concentration of test compounds were 50 μg/ml, IC50: Compound concentration required to inhibit enzyme activity by 50 %, NI: No inhibition, SEM 
= Standard error mean; each value is the mean of three values.  
 
The three compounds 4a, 4b and 4c revealed potent inhibitory 
activity against GSTP1 of 98.4±0.03, 98.5±0.05 and 98.8±0.03 % 
with IC50 of 4.3±0.29, 3.43±0.32and 1.5±0.18 μM, respectively. 
GSTP1 activity inhibition assay 
An indication of the degree of selectivity of the newly synthesized 
compounds 2-5 towards GSTP1 has been obtained by inhibition 
studies, which fulfilled the inhibitory effect (%) and IC50 (μM) values 
at a concentration of 50 μg ml-1 (table 3). 
Molecular docking study 
Docking study using MOE 2008.10 programmes was performed. It is 
used to predict the binding modes and orientation of the most 
promising anticancer compounds 4a, 4b and 4d at the active site of 
the ATP binding site of GSTP1. The coordinates of the GSTP1 
structure were obtained from the crystal structure of GSTP1 with its 
inhibitor (PDB ID: 3GUS).  
The root mean square difference (RMSD) between the top docking 
pose and original crystallographic geometry of co-crystallized ligand 
NBDHEX was 0.92 A °. It exhibited several hydrophobic interactions 
with residues shaping the H-site of the GSTP1 enzyme, including 
Tyr7, Phe8, Val35, Trp38, Gln39, Ile104, and above all, Tyr108, 
which engages an aromatic ring stacking interaction with the 
benzoxadiazole ring. There were two hydrogen bonds: one H-bond 
was binding NO2 group of ligand with Arg13 indirectly by a water 
molecule; the other H-bond was linking OH group with Gln39 [4]. 
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From table 4, it was found that the compounds under study 
exhibited good fitting inside the binding site of the protein molecular 
surface and having minimum binding energy ranged from-6.72 to-
8.23 k cal mol-1. 
 
Table 4: Docking results of the compounds 4a, 4b and 4d with GSTP1 using MOE software version 2008.10 
Compd. No. Docking score 
K cal mol-1 
Amino acid residues 
(bond length Ao) 
Atoms of compound Type of bond 
4a -6.72 Gln39(2.93) O(CO) (COOH) H-don 
4b -7.46 Gln39(2.69) O(CO) (COOH) H-don 









Oxygens of C=O groups act as H-donors in 4a and 4b forming H-bond with Gln39 and H-acceptor in 4d. Furthermore, there are two hydrogen bonds 
formed in 4d, one between oxygen of the carbonyl group of the thiazole ring and Trp38 and the other between oxygen of 4-methoxyphenyl and 
Gln51 (fig. 2, 3). 
 
 
Fig. 2: The proposed binding mode of compound 4b docked in 
the active site of GSTP1; A and B showing 2D and 3D ligand-
receptor interactions (hydrogen bonds are illustrated as 
arrows; C atoms are colored gray, N blue and O red) 
 
 
Fig. 3: The proposed binding mode of compound 4d docked in 
the active site of GSTP1; A and B showing 2D and 3D ligand-
receptor interactions (hydrogen bonds are illustrated as 
arrows; C atoms are colored gray, N blue and O red) 
 
From a survey of previous results, it is clear that the thiazole-
pyrazole backbone of compounds 4a, 4b, 4d is crucial for the 
cytotoxic activity against the three types of carcinoma (HEPG-2, PC-3 
and A-549) cell lines and inhibitory effect against GSTP1 enzyme. 
This may be due to insertion of–CH2COOH group at the 
thiazolidinonyl scaffold which is responsible for formation of H-
bond between oxygen of the C=O group and Gln39 similarly with the 
co-crystallized ligand NBDHEX [4]. Substitution of the phenyl ring at 
N3 of thiazolidinonyl moiety with an electron donating group (4d) 
increased cytotoxic activity and GSTP1 selectivity due to good 
binding to the active site of the enzyme by another H-bond between 
oxygen of 4-methoxyphenyl and Gln51.  
Differently, compound 4c with an electron withdrawing group (F) at 
the para position of the phenyl ring displayed a lower affinity 
towards GSTP1 and decreased anticancer activity against the three 
carcinoma cell lines. Compounds 4a, 4b and 4d may represent a new 
group of GSTP1 inhibitors with antiproliferative activity in liver and 
prostate carcinoma and are worthy of further study. 
CONCLUSION 
A new series of substituted thiazoles incorporated in pyrazole 
moieties (2-5) was synthesized starting from 1-(3-chlorophenyl)-3-
(4-methoxyphenyl)-1H-pyrazole-4-carboxaldehyde (1). The new 
target compounds 2-5 were screened for their GSTP1 inhibition and 
cytotoxic activity against HEPG-2, PC-3 and A-549 cell lines. The 
most promising cytotoxic compounds 4a, 4b and 4d were employed 
for docking study towards GSTP1 (PDB ID: 3GUS) and exhibited 
efficient binding mode at the active site of the enzyme. 
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